{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:26:38Z","timestamp":1776237998891,"version":"3.50.1"},"reference-count":65,"publisher":"Probiologists Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.probiologists.com\/policies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Signal"],"abstract":"<jats:p>New efficacious and safe therapies are needed for patients with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. A bioinformatic approach comparing human PDAC tumors to normal pancreas identified differentially expressed G protein-coupled receptors (GPCRs). The GPCRs with higher differential expression in PDAC included the histamine H1 receptor (HRH1), which, on average, is ~20-fold higher expressed in PDAC tumors. HRH1 is readily targetable by approved H1-antihistamines. Studies with human and murine PDAC tumor cells revealed that HRH1 agonists increase intracellular calcium in cancer cells and promote their migration and invasion. Fexofenadine, an H1-antihistamine, decreased pancreas tumor size and altered expression of cancer relevant genes in a mouse model of PDAC. These findings complement data for HRH1 and H1-antihistamines, especially second generation cationic amphiphilic antihistamines, observed in numerous other cancers. Studies are needed to determine if H1-antihistamines can augment anti-tumor response by current therapeutics and improve outcomes for PDAC patients. These findings with HRH1 suggest that other differentially expressed GPCRs with approved drugs may be therapeutic targets for PDAC and other cancers.<\/jats:p>","DOI":"10.46439\/signaling.4.094","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:36:24Z","timestamp":1776234984000},"page":"37","source":"Crossref","is-referenced-by-count":0,"title":["Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistamines?"],"prefix":"10.46439","volume":"4","author":[{"given":"Paul A.","family":"Insel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrak","family":"Javadi-Paydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"25620","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Dominguez AA, Perz MT, Xu Y, Cedillo LG, Huang OD, McIntyre CA, et al. Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC. Cancers (Basel). 2024 Oct 23;16(21):3564.","DOI":"10.3390\/cancers16213564"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Chick RC, Pawlik TM. Updates in Immunotherapy for Pancreatic Cancer. J Clin Med. 2024 Oct 26;13(21):6419.","DOI":"10.3390\/jcm13216419"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Pradeep R, Isbeih NJ, Abraham FF, Noori E, Yeung ZP, Kundranda MN. KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. J Clin Med. 2026 Jan 21;15(2):873.","DOI":"10.3390\/jcm15020873"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913\u201321.","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Sriram K, Insel PA. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol Pharmacol. 2018 Apr;93(4):251\u20138.","DOI":"10.1124\/mol.117.111062"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Lorente JS, Sokolov AV, Ferguson G, Schi\u00f6th HB, Hauser AS, Gloriam DE. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025 Jun;24(6):458\u201379.","DOI":"10.1038\/s41573-025-01139-y"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016 Jun;48(6):675\u201380.","DOI":"10.1038\/ng.3549"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Ang CS, Shen JP, Hardy-Abeloos CJ, Huang JK, Ross JS, Miller VA, et al. Genomic Landscape of Appendiceal Neoplasms. JCO Precis Oncol. 2018 Aug 8;2:PO.17.00302.","DOI":"10.1200\/PO.17.00302"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Rueda A, Serna N, Mangues R, Villaverde A, Unzueta U. Targeting the chemokine receptor CXCR4 for cancer therapies. Biomark Res. 2025 May 1;13(1):68.","DOI":"10.1186\/s40364-025-00778-y"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Stagg J, Gutkind JS. Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies. Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):315\u201331.","DOI":"10.1146\/annurev-pharmtox-061724-080852"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Snead AN, Insel PA. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J. 2012 Nov;26(11):4540\u20137.","DOI":"10.1096\/fj.12-213496"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Insel PA, Wilderman A, Zambon AC, Snead AN, Murray F, Aroonsakool N, et al. G Protein-Coupled Receptor (GPCR) Expression in Native Cells: \"Novel\" endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol Pharmacol. 2015 Jul;88(1):181\u20137.","DOI":"10.1124\/mol.115.098129"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, et al. GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front Pharmacol. 2018 May 22;9:431.","DOI":"10.3389\/fphar.2018.00431"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Insel PA, Sriram K, Gorr MW, Wiley SZ, Michkov A, Salmer\u00f3n C, et al. GPCRomics: An Approach to Discover GPCR Drug Targets. Trends Pharmacol Sci. 2019 Jun;40(6):378\u201387.","DOI":"10.1016\/j.tips.2019.04.001"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J. 2018 Mar;32(3):1170\u20131183.","DOI":"10.1096\/fj.201700834R"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Sriram K, Wiley SZ, Moyung K, Gorr MW, Salmer\u00f3n C, Marucut J, et al. Detection and Quantification of GPCR mRNA: An Assessment and Implications of Data from High-Content Methods. ACS Omega. 2019 Sep 30;4(16):17048-59.","DOI":"10.1021\/acsomega.9b02811"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Sriram K, Salmer\u00f3n C, Di Nardo A, Insel PA. Detection of GPCR mRNA Expression in Primary Cells Via qPCR, Microarrays, and RNA-Sequencing. Methods Mol Biol. 2021;2268:21\u201342.","DOI":"10.1007\/978-1-0716-1221-7_2"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Sriram K, Moyung K, Corriden R, Carter H, Insel PA. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019 Nov 25;17(11):e3000434.","DOI":"10.1371\/journal.pbio.3000434"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Alexander SPH, Davenport AP, Kelly E, Gibb AJ, Mathie AA, Peach CJ, et al. The Concise Guide to PHARMACOLOGY 2025\/26: G protein-coupled receptors. Br J Pharmacol. 2025 Dec;182 Suppl 1:S24-S151.","DOI":"10.1111\/bph.70232"},{"key":"ref19","unstructured":"20. Francis T, Graf A, Hodges K, Kennedy L, Hargrove L, Price M, et al. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg Nutr. 2013 Aug;2(4):216\u201326."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Massari NA, Nicoud MB, Medina VA. Histamine receptors and cancer pharmacology: an update. Br J Pharmacol. 2020 Feb;177(3):516\u201338.","DOI":"10.1111\/bph.14535"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Zhong P, Nakata K, Oyama K, Higashijima N, Sagara A, Date S, et al. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. J Exp Clin Cancer Res. 2024 May 8;43(1):138.","DOI":"10.1186\/s13046-024-03060-5"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Salmer\u00f3n C, Tom\u00e1s Bort E, Sriram K, Javadi-Paydar M, Smitham JE, Pham K, et al. Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. J Pharmacol Exp Ther. 2025 May;392(5):103573.","DOI":"10.1016\/j.jpet.2025.103573"},{"key":"ref23","unstructured":"24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28;483(7391):603\u20137."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Huang BZ, Le Marchand L, Haiman CA, Monroe KR, Wilkens LR, Zhang ZF, et al. Atopic allergic conditions and pancreatic cancer risk: Results from the Multiethnic Cohort Study. Int J Cancer. 2018 May 15;142(10):2019\u201327.","DOI":"10.1002\/ijc.31241"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol. 2021 Apr;14(4):101029.","DOI":"10.1016\/j.tranon.2021.101029"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Schneider EH, Seifert R. Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System. Handb Exp Pharmacol. 2017;241:63\u2013118.","DOI":"10.1007\/164_2016_124"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646\u201374.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010 Apr 15;16(8):2257\u201365.","DOI":"10.1158\/1078-0432.CCR-09-1230"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y, et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011 Nov 15;17(22):7015\u201323.","DOI":"10.1158\/1078-0432.CCR-11-0607"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013 Jul 1;73(13):3927\u201337.","DOI":"10.1158\/0008-5472.CAN-12-4479"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Longo V, Tamma R, Brunetti O, Pisconti S, Argentiero A, Silvestris N, et al. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. Clin Exp Med. 2018 Aug;18(3):319\u201323.","DOI":"10.1007\/s10238-018-0493-6"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. Raveendran VV, Smith DD, Tan X, Sweeney ME, Reed GA, Flynn CA, et al. Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-\/- mice. PLoS One. 2014 Jul 14;9(7):e102165.","DOI":"10.1371\/journal.pone.0102165"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Eylemer Mocan E, Yeked\u00fcz E, Karata\u015f G, Yazgan SC, K\u00f6ksoy EB, \u00c7ay \u015eenler F, et al. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients. Anticancer Drugs. 2024 Feb 1;35(2):190\u201394.","DOI":"10.1097\/CAD.0000000000001498"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Weitz JR, Tiriac H, Hurtado de Mendoza T, Wascher A, Lowy AM. Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. Cancers (Basel). 2021 Oct 5;13(19):4991.","DOI":"10.3390\/cancers13194991"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. Anand A, Liu B, Dicroce Giacobini J, Maeda K, Rohde M, J\u00e4\u00e4ttel\u00e4 M. Cell Death Induced by Cationic Amphiphilic Drugs Depends on Lysosomal Ca2+ Release and Cyclic AMP. Mol Cancer Ther. 2019 Sep;18(9):1602\u201314.","DOI":"10.1158\/1535-7163.MCT-18-1406"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Liu B, Chen R, Zhang Y, Huang J, Luo Y, Rosth\u00f8j S, et al. Cationic amphiphilic antihistamines inhibit STAT3 via Ca2+-dependent lysosomal H+ efflux. Cell Rep. 2023 Feb 28;42(2):112137.","DOI":"10.1016\/j.celrep.2023.112137"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38. Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013 Sep 9;24(3):379\u201393.","DOI":"10.1016\/j.ccr.2013.08.003"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Chiang CH, Chiang CH, Peng CY, Hsia YP, See XY, Horng CS, et al. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors. Eur J Cancer. 2022 Oct;174:1\u20139.","DOI":"10.1016\/j.ejca.2022.07.006"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Chiang CH, Chiang CH, Hsia YP, Chen BS, Jaroenlapnopparat A, Chiang CH, et al. The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. J Gastrointest Cancer. 2024 Mar;55(1):175\u20137.","DOI":"10.1007\/s12029-023-00969-6"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41. Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022 Jan 10;40(1):36\u201352.e9.","DOI":"10.1016\/j.ccell.2021.11.002"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42. Verdoodt F, Dehlendorff C, J\u00e4\u00e4ttel\u00e4 M, Strauss R, Potteg\u00e5rd A, Hallas J, et al. Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay. J Natl Cancer Inst. 2020 Sep 1;112(9):964\u20137.","DOI":"10.1093\/jnci\/djz217"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43. Ellegaard AM, Dehlendorff C, Vind AC, Anand A, Cederkvist L, Petersen NHT, et al. Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment. EBioMedicine. 2016 Jul;9:130\u20139.","DOI":"10.1016\/j.ebiom.2016.06.013"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44. Hamid O, Hamidi N. Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings. Curr Med Res Opin. 2024 Dec;40(12):2139\u201346.","DOI":"10.1080\/03007995.2024.2427323"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45. Nagy S, Denis O, Hussein A, Kesselman MM. The Impact of Antihistamines on Immunotherapy: A Systematic Review. Cureus. 2025 Feb 21;17(2):e79421.","DOI":"10.7759\/cureus.79421"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46. Fritz I, Wagner P, Broberg P, Einefors R, Olsson H. Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival. Acta Oncol. 2020 Sep;59(9):1103\u20139.","DOI":"10.1080\/0284186X.2020.1769185"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47. Bakhtiari E, Moazzen N, Amirabadi A, Ahanchian H. The clinical relationship between histamine-1 receptor antagonists and risk of cancer: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2023 Jan;23(1):87\u201394.","DOI":"10.1080\/14737140.2023.2157265"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48. Wang M, Wei X, Shi L, Chen B, Zhao G, Yang H. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction. Int J Mol Med. 2014 Apr;33(4):1019\u201326.","DOI":"10.3892\/ijmm.2014.1649"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49. Nguyen PL, Cho J. Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets. Biomolecules. 2021 Aug 18;11(8):1232.","DOI":"10.3390\/biom11081232"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50. Zhao J, Hou Y, Yin C, Hu J, Gao T, Huang X, et al. Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma. Oncogene. 2020 Feb;39(8):1724\u201338.","DOI":"10.1038\/s41388-019-1093-y"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51. Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, et al. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol. 2022 Apr 10;40(11):1206\u201319.","DOI":"10.1200\/JCO.21.01802"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52. Wu SY, Chen WM, Chen YC, Chiang MF, Lee MC, Soong RS. Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus. Diabetes Metab. 2023 Jan;49(1):101393.","DOI":"10.1016\/j.diabet.2022.101393"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53. Chen J, Liu G, Wang X, Hong H, Li T, Li L, et al. Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling. Cell Stem Cell. 2022 Nov 3;29(11):1531\u201346.","DOI":"10.1016\/j.stem.2022.09.009"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54. Yadav P, Vengoji R, Jain M, Batra SK, Shonka N. Pathophysiological role of histamine signaling and its implications in glioblastoma. Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189146.","DOI":"10.1016\/j.bbcan.2024.189146"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55. Wang K, Zhao P, Zhu X, Tang F, Chen H, Zhang Y, et al. HRH1-targeting mAb: a precision therapeutic strategy for Glioblastoma. Oncogene. 2025 Dec;44(47):4601\u201314.","DOI":"10.1038\/s41388-025-03613-8"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56. Ding YF, Ho KH, Lee WJ, Chen LH, Hsieh FK, Tung MC, et al. Cyclic increase in the histamine receptor H1-ADAM9-Snail\/Slug axis as a potential therapeutic target for EMT-mediated progression of oral squamous cell carcinoma. Cell Death Dis. 2025 Mar 20;16(1):191.","DOI":"10.1038\/s41419-025-07507-1"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57. Shi A, Liu Z, Fan Z, Li K, Liu X, Tang Y, et al. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment. Gut. 2024 Jul 11;73(8):1350\u201363.","DOI":"10.1136\/gutjnl-2023-331715"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58. Fern\u00e1ndez-Nogueira P, Noguera-Castells A, Fuster G, Recalde-Percaz L, Moragas N, L\u00f3pez-Plana A, et al. Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer. Cancer Lett. 2018 Jun 28;424:70\u201383.","DOI":"10.1016\/j.canlet.2018.03.014"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59. Ma J, Qi J, Li S, Zhang C, Wang H, Shao L, et al. Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820926591.","DOI":"10.1177\/1533033820926591"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60. Pan Z, Li SJ, Guo H, Li ZH, Fei X, Chang SM, et al. Ebastine exerts antitumor activity and induces autophagy by activating AMPK\/ULK1 signaling in an IPMK-dependent manner in osteosarcoma. Int J Biol Sci. 2023 Jan 1;19(2):537\u20131.","DOI":"10.7150\/ijbs.69541"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61. Shi Z, Fultz RS, Engevik MA, Gao C, Hall A, Major A, et al. Distinct roles of histamine H1- and H2-receptor signaling pathways in inflammation-associated colonic tumorigenesis. Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G205\u2013G216.","DOI":"10.1152\/ajpgi.00212.2018"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62. Wake H, Hatipoglu OF, Nishinaka T, Watanabe M, Toyomura T, Mori S, et al. Histamine induces vascular endothelial cell proliferation via the histamine H1 receptor-extracellular regulated protein kinase 1\/2-cyclin D1\/cyclin-dependent kinase 4\/6 axis. Microvasc Res. 2026 Jan;163:104866.","DOI":"10.1016\/j.mvr.2025.104866"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63. Baker JG, Sloan EK, Pfleger KDG, McCormick PJ, Salmer\u00f3n C, Insel PA. Pancreatic Ductal Adenocarcinoma, \u03b2-blockers, and Antihistamines: A Clinical Trial Is Needed. Function (Oxf). 2025 Feb 12;6(1):zqae050.","DOI":"10.1093\/function\/zqae050"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64. Shakiba M, Tuveson DA. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat Immunol. 2025 May;26(5):678\u201391.","DOI":"10.1038\/s41590-025-02134-6"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65. Achim E, P\u00eerlici E, Cristea C, Tertis M. Design and Efficacy of Oncolytic Viruses and Antitumor Vaccines: A Dead End in the Immunotherapy of Pancreatic Cancer? Int J Mol Sci. 2025 Oct 2;26(19):9640.","DOI":"10.3390\/ijms26199640"}],"container-title":["Cell Signaling"],"original-title":[],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:36:56Z","timestamp":1776235016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probiologists.com\/article\/histamine-h1-receptor-a-target-to-treat-pancreatic-ductal-adenocarcinoma-%28pdac%29-by-repurposing-approved-h1-antihistamines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,25]]}},"URL":"https:\/\/doi.org\/10.46439\/signaling.4.094","relation":{},"ISSN":["2837-8253"],"issn-type":[{"value":"2837-8253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}